The valve may now be used to replace failing heart valves previously implanted in high risk patients, according to the report. Clinicians place the Sapein 3 valve into the failing valve through a blood vessel or small incision in the patient’s chest, which offers a less invasive treatment option than repeat open heart surgery.
The FDA originally approved the valve as a replacement for a patient’s natural valve when open heart surgery is deemed too risky.
More articles on supply chain:
Premier: 9 policy recommendations to fix high drug costs
6 FDA decisions to keep an eye on in June
Eli Lilly CFO to retire at year-end
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
